Descripción de la empresa
GRAIL, Inc. operates as a commercial-stage healthcare entity dedicated to providing multi-cancer early detection testing and services within the United States and international markets. The company focuses on offering Galleri, a specialized cancer screening test designed for asymptomatic individuals over the age of 50, alongside diagnostic aids intended to accelerate cancer detection processes. This business falls squarely within the Healthcare sector and the Diagnostics & Research industry, positioning the firm to capture value from advancements in genomic research and early detection technologies. With a market capitalization of $2.02 billion, an annual revenue of $147.17 million, and an employee base of 910, the company demonstrates a significant operational footprint. These valuation and revenue figures indicate that GRAIL has attracted substantial investor interest despite being in a development phase, suggesting the market views its technology and service portfolio as a critical asset in the evolving landscape of preventative oncology diagnostics.
Salud financiera
The company reported a revenue of $147.17 million over the trailing twelve months, yet it recorded a net income of -$408,351,008 and an EBITDA of -$377,852,992, revealing a substantial gap between top-line growth and profitability. This significant disparity between revenue and net income indicates a cost structure where expenses, likely driven by research and development and scaling operations, far exceed current earnings. Free cash flow stands at -$108,893,128, which highlights that the company is currently burning cash rather than generating liquidity from its core activities. This negative cash flow situation implies limited immediate financial flexibility to fund expansion without external capital injections, although the firm holds $904.43 million in cash reserves. The balance sheet presents a leveraged profile with total debt of $54.86 million against a debt-to-equity ratio of 2.13, while the current ratio of 11.97 suggests robust short-term liquidity relative to obligations. Despite holding significant cash, the return on equity is -16.1% and the return on assets is -11.3%, metrics that reveal management has not yet generated positive returns on the capital invested in the business. Furthermore, the gross margin of 48.5% contrasts sharply with an operating margin of -285.4% and a profit margin of -277.5%, illustrating that while the core product is priced well above variable costs, overhead and structural costs are currently destroying operating profitability.
Evaluación de valoración
Valuation multiples for GRAIL reflect its pre-profitability status, with a trailing P/E ratio marked as N/A due to negative earnings, while the forward P/E is calculated at -5.43, implying expectations of continued negative earnings or a long path to profitability. The price-to-book ratio stands at 0.77, indicating that the market values the company at a discount relative to its net asset book value. Alternative valuation metrics provide further context, as the price-to-sales ratio is 13.70 and the EV/EBITDA is -3.09, suggesting investors are pricing the company based on revenue multiples rather than earnings power. The stock has experienced high volatility, trading between a 52-week low of $20.53 and a 52-week high of $118.84, with the current market price situated significantly below the recent highs. The beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index based on the available data. These valuation characteristics suggest the market is assessing the company primarily on its potential future growth trajectory and technological moat rather than current financial performance.
Growth & Income
Revenue growth year-over-year is recorded at 14.0%, while earnings growth is N/A due to the company's ongoing losses, indicating that profitability is lagging behind top-line expansion. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders and instead reinvests earnings into research, development, and operational scaling. This reinvestment strategy is typical for early-stage biotech firms aiming to secure market dominance before achieving widespread commercial profitability. The overall growth and income profile is defined by strong revenue expansion in a high-need market, coupled with a complete reliance on external capital to fund operations and absorb the substantial losses inherent in scaling a diagnostic platform.